ClinicalTrials.gg
CompletedNCT04788511STEP-HFpEFUpdated Dec 5, 2025Results posted

Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity

A Phase 3 interventional study of Semaglutide and Placebo (semaglutide) in Obesity, sponsored by Novo Nordisk A/S. Completed at 146 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
529
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.

Enrollment
13th of 143
529 · median 100
Started
2021
with 9 others
Phase 3
42 of 143
10 open now
Registered
26th of 143
by date
Lead sponsor
41 of 143
Novo Nordisk A/S

Among the 143 studies testing semaglutide in Obesity, this one is the 13th largest by enrollment, is one of 10 that started in 2021, is one of 42 in phase 3, and was the 26th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

63 more — sign in →

By country, each count listing its studies:

All 68 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies testing semaglutide in Obesity, or all of them as a file.
02

Study summary

This study will look at how the participants daily life is affected by their heart failure. The study will also look at the change in participants body weight from the start to the end of the study. This is to compare the effect on heart failure symptoms and on body weight in people taking semaglutide (a new medicine) to people taking "dummy" medicine.

Participants will either get semaglutide or "dummy" medicine - which treatment participants get is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach area, thigh or upper arm.

During the study participants will have talks with the study staff about healthy lifestyle choices including healthy food and physical activity.

The study will last for approximately 59 weeks. Participants will have 11 clinic visits and 1 phone call with the study doctor. Women: Women cannot take part if they are pregnant, breast-feeding or plan to become pregnant during the study period.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, age above or equal to 18 years at the time of signing .
  • (BMI) greater than or equal to 30.0 kg/m\^2
  • (NYHA) Class II-IV
  • (LVEF) greater than or equal to 45 percentage at screening

Exclusion criteria

Exclusion Criteria:

  • A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records
  • (HbA1c) greater than or equal to 6.5 percentage (48 mmol/mol) based on latest available value from medical records, no older than 3 months or if unavailable a local measurement at screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
529 participants (actual)

Study arms

  • Experimental
    Semaglutide

    All participants will receive either semaglutide 2.4 mg once weekly or placebo once weekly as add-on to standard of care. During the first 16 weeks, the dose of semaglutide or placebo will be gradually escalated from 0.25 mg once weekly until target dose.

    Drug: Semaglutide

  • Placebo comparator
    Placebo (semaglutide)

    All participants will receive either semaglutide 2.4 mg once weekly or placebo once weekly as add-on to standard of care. During the first 16 weeks, the dose of semaglutide or placebo will be gradually escalated from 0.25 mg once weekly until target dose.

    Drug: Placebo (semaglutide)

Interventions

  • Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Dose gradually escalated from 0.25 mg until target dose. The study will last for approximately 59 weeks.

  • DrugPlacebo (semaglutide)

    Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. The study will last for approximately 59 weeks.

06

What researchers measure

Primary outcomes

  1. Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)

    The KCCQ is a standardized 23-item, self-administered instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, quality of life, and social limitation. The overall summary score and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. KCCQ-CSS includes the symptom and physical limitation domains of the KCCQ. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

    Time frame: From baseline (week 0) to end of treatment (week 52)

  2. Change in Body Weight

    Change in body weight from baseline (week 0) to end of treatment (week 52) is presented. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

    Time frame: From baseline (week 0) to end of treatment (week 52)

Secondary outcomes

  1. Change in Six-minute Walking Distance (6MWD)

    Observed mean change from baseline (week 0) in 6 minutes walking distance (6MWD) test to end of treatment (week 52) is presented. The 6MWD is a common test of functional exercise capacity that assesses the distance a participant can walk in 6 minutes. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

    Time frame: From baseline (week 0) to end of treatment (week 52)

  2. The Hierarchical Composite Endpoint: Percentage of Wins of Participant Pairs

    The hierarchical composite outcome measure from baseline (week 0) to end of study (week 57) consists of the components: time to all-cause death, number of heart failure events requiring hospitalization or urgent heart failure visit, time to first heart failure event requiring hospitalization or urgent heart failure visit, difference at least 15 in KCCQ CSS change from baseline to 52 weeks, difference at least 10 in KCCQ CSS change from baseline to 52 weeks, difference at least 5 in KCCQ CSS change from baseline to 52 weeks and difference at least 30 meters in six-minute walking distance change from baseline to 52 weeks. It was analyzed by the win-ratio approach using all participants pairs across treatment groups. Overall summary of wins in each treatment group is presented. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as uninterrupted time interval from date of randomization to date of last contact with trial site.

    Time frame: From baseline (week 0) to end of study (week 57)

  3. Change in C-Reactive Protein (CRP): Ratio to Baseline

    Change in high sensitivity C-reactive protein measured in ratio of C-reactive protein to baseline (week -2) at end of treatment (week 52) is presented. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

    Time frame: From baseline (week -2) to end of treatment (week 52)

  4. Percentage of Participants Achieving 10 Percent (%) Weight Loss (Yes/No)

    Percentage of participants who achieved 10% weight loss (yes/no) from baseline (week 0) to end of treatment (week 52) is presented. In the reported data, 'Yes' infers percentage of participants who have achieved 10% weight loss whereas 'No' infers percentage of participants who have not achieved 10% weight loss. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

    Time frame: From baseline (week 0) to end of treatment (week 52)

  5. Percentage of Participants Achieving 15% Weight Loss (Yes/No)

    Percentage of participants who achieved 15% weight loss (yes/no) from baseline (week 0) to end of treatment (week 52) is presented. In the reported data, 'Yes' infers percentage of participants who have achieved 15% weight loss whereas 'No' infers percentage of participants who have not achieved 15% weight loss. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

    Time frame: From baseline (week 0) to end of treatment (week 52)

  6. Percentage of Participants Achieving 20% Weight Loss (Yes/No)

    Percentage of participants who achieved 20% weight loss (yes/no) from baseline (week 0) to end of treatment (week 52) is presented. In the reported data, 'Yes' infers percentage of participants who have achieved 20% weight loss whereas 'No' infers percentage of participants who have not achieved 20% weight loss The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

    Time frame: From baseline (week 0) to end of treatment (week 52)

  7. Percentage of Participants Improving 5 Points or More in KCCQ Clinical Summary Score (Yes/No)

    Percentage of participants improving 5 points or more in KCCQ-CSS from baseline to end of treatment is presented. The KCCQ is standardized 23-item, self-administered instrument that quantifies heart failure symptoms(frequency, severity, and recent change), physical limitation, quality of life, and social limitation. KCCQ-CSS includes the symptom and physical limitation domains of the KCCQ. Scores are transformed to range of 0-100, in which higher scores reflect better health status. In the reported data, 'Yes' infers percentage of participants who have improved 5 points or more in score whereas 'No' infers percentage of participants who have not improved 5 points or more in score. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

    Time frame: From baseline (week 0) to end of treatment (week 52)

  8. Percentage of Participants Improving 10 Points or More in KCCQ Clinical Summary Score (Yes/No)

    Percentage of participants improving 10 points or more in KCCQ-CSS from baseline to end of treatment is presented. The KCCQ is standardized 23-item, self-administered instrument that quantifies heart failure symptoms(frequency, severity, and recent change), physical limitation, quality of life, and social limitation. KCCQ-CSS includes the symptom and physical limitation domains of the KCCQ. Scores are transformed to range of 0-100, in which higher scores reflect better health status. In reported data, 'Yes' infers percentage of participants who have improved 5 points or more in score whereas 'No' infers percentage of participants who have not improved 10 points or more in score. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

    Time frame: From baseline (week 0) to end of treatment (week 52)

  9. Change in KCCQ Overall Summary Score (KCCQ-OSS)

    The KCCQ is a standardized 23-item, self-administered instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, quality of life, and social limitation. The overall summary score and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. KCCQ-CSS includes the symptom and physical limitation domains of the KCCQ while KCCQ-OSS includes the symptom, physical limitation, quality of life, and social limitation domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

    Time frame: From baseline (week 0) to end of treatment (week 52)

  10. Percentage of Participants Achieving Threshold for Clinically Meaningful Within-participants Change in KCCQ-CSS (PGI-S)

    The patient global impression of status (PGI-S) for KCCQ was used to rate participants' symptoms of heart failure using 4-category ordinal scale (no symptoms, mild, moderate, severe). KCCQ is standardized 23-item, self-administered instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, quality of life, and social limitation. OSS and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. KCCQ-CSS includes symptom and physical limitation domains of the KCCQ. Scores are transformed to range of 0-100, in which higher scores reflect better health status. Outcome measure was evaluated based on data from in-trial period. In-trial period was defined as uninterrupted time interval from date of randomization to date of last contact with trial site. The threshold was defined as mean change in KCCQ-CSS in those participants with one-category improvement in PGI-S from baseline to week 52.

    Time frame: From baseline (week 0) to end of treatment (week 52)

  11. Percentage of Participants Achieving Threshold for Clinically Meaningful Within-participants Change in 6MWD (PGI-S)

    Observed mean change from baseline in 6 minutes walking distance (6MWD) test using PGI-S is evaluated for this outcome measure. The 6MWD is a common test of functional exercise capacity that assesses the distance a participant can walk in 6 minutes. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site. The threshold was defined as the mean change in 6MWD in those participants with an one-category improvement in PGI-S from baseline to week 52.

    Time frame: From baseline (week 0) to end of treatment (week 52)

  12. Change in Systolic Blood Pressure (SBP)

    Observed mean change in systolic blood pressure from baseline (week -2) to end of treatment (week 52) is presented. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

    Time frame: From baseline (week -2) to end of treatment (week 52)

  13. Change in Waist Circumference

    Change waist circumference from baseline (week 0) to end of the treatment (visit 52) presented. Waist circumference is defined as the abdominal circumference located midway between the lower rib margin and the iliac crest. Measurement must be obtained in standing position with a non-stretchable measuring tape and to the nearest cm or inch. The tape should touch the skin but not compress soft tissue and twists in the tape should be avoided. The participant should be asked to breathe normally. The same measuring tape should be used throughout the trial. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

    Time frame: From baseline (week 0) to end of treatment (visit 52)

07

Results

Posted Jun 11, 2024

Participant flow

The trial was conducted at 83 sites in 13 countries, as follows: Argentina (6), Australia (5), Hungary (8), Czech Republic (5), Poland (6), Spain (3), Netherlands (6), Denmark (3), United States (16), Canada (4), Israel (5), Germany (7) and United Kingdom (9).

Participant flow — Overall Study
MilestoneSemaglutide 2.4 mgPlacebo
Started263266
Full analysis set (fas)263266
Safety analysis set (sas)263266
Completed256254
Not completed712
Withdrew: Withdrawal by subject21
Withdrew: Lost to follow-up27
Withdrew: Death34

Outcome measures

PrimaryChange in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)

The KCCQ is a standardized 23-item, self-administered instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, quality of life, and social limitation. The overall summary score and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. KCCQ-CSS includes the symptom and physical limitation domains of the KCCQ. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

Time frame:
From baseline (week 0) to end of treatment (week 52)
Reported as:
Mean · Score on a scale
Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)
Score on a scaleSemaglutide 2.4 mgPlacebo
Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)16.8 ± 17.910.3 ± 17.3
Statistical analysis
  • Semaglutide 2.4 mg vs Placebo · ANCOVA · p = <0.0001 · Estimated treatment difference: 7.8 · 95% CI 4.8 to 10.9
PrimaryChange in Body Weight

Change in body weight from baseline (week 0) to end of treatment (week 52) is presented. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

Time frame:
From baseline (week 0) to end of treatment (week 52)
Reported as:
Mean · Percentage of body weight
Change in Body Weight
Percentage of body weightSemaglutide 2.4 mgPlacebo
Change in Body Weight-13.9 ± 8.1-2.5 ± 5.6
Statistical analysis
  • Semaglutide 2.4 mg vs Placebo · ANCOVA · p = <0.0001 · Estimated treatment difference: -10.7 · 95% CI -11.9 to -9.4
SecondaryChange in Six-minute Walking Distance (6MWD)

Observed mean change from baseline (week 0) in 6 minutes walking distance (6MWD) test to end of treatment (week 52) is presented. The 6MWD is a common test of functional exercise capacity that assesses the distance a participant can walk in 6 minutes. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

Time frame:
From baseline (week 0) to end of treatment (week 52)
Reported as:
Mean · Meters
Change in Six-minute Walking Distance (6MWD)
MetersSemaglutide 2.4 mgPlacebo
Change in Six-minute Walking Distance (6MWD)23.5 ± 59.25.8 ± 62.7
SecondaryThe Hierarchical Composite Endpoint: Percentage of Wins of Participant Pairs

The hierarchical composite outcome measure from baseline (week 0) to end of study (week 57) consists of the components: time to all-cause death, number of heart failure events requiring hospitalization or urgent heart failure visit, time to first heart failure event requiring hospitalization or urgent heart failure visit, difference at least 15 in KCCQ CSS change from baseline to 52 weeks, difference at least 10 in KCCQ CSS change from baseline to 52 weeks, difference at least 5 in KCCQ CSS change from baseline to 52 weeks and difference at least 30 meters in six-minute walking distance change from baseline to 52 weeks. It was analyzed by the win-ratio approach using all participants pairs across treatment groups. Overall summary of wins in each treatment group is presented. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as uninterrupted time interval from date of randomization to date of last contact with trial site.

Time frame:
From baseline (week 0) to end of study (week 57)
Reported as:
Number · Percentages of wins of participant pairs
The Hierarchical Composite Endpoint: Percentage of Wins of Participant Pairs
Percentages of wins of participant pairsSemaglutide 2.4 mgPlacebo
The Hierarchical Composite Endpoint: Percentage of Wins of Participant Pairs60.134.9
SecondaryChange in C-Reactive Protein (CRP): Ratio to Baseline

Change in high sensitivity C-reactive protein measured in ratio of C-reactive protein to baseline (week -2) at end of treatment (week 52) is presented. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

Time frame:
From baseline (week -2) to end of treatment (week 52)
Reported as:
Geometric mean · Ratio of C-reactive protein
Change in C-Reactive Protein (CRP): Ratio to Baseline
Ratio of C-reactive proteinSemaglutide 2.4 mgPlacebo
Change in C-Reactive Protein (CRP): Ratio to Baseline0.55 ± 121.50.92 ± 105.3
SecondaryPercentage of Participants Achieving 10 Percent (%) Weight Loss (Yes/No)

Percentage of participants who achieved 10% weight loss (yes/no) from baseline (week 0) to end of treatment (week 52) is presented. In the reported data, 'Yes' infers percentage of participants who have achieved 10% weight loss whereas 'No' infers percentage of participants who have not achieved 10% weight loss. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

Time frame:
From baseline (week 0) to end of treatment (week 52)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving 10 Percent (%) Weight Loss (Yes/No)
Percentage of participantsSemaglutide 2.4 mgPlacebo
No34.190.5
Yes65.99.5
SecondaryPercentage of Participants Achieving 15% Weight Loss (Yes/No)

Percentage of participants who achieved 15% weight loss (yes/no) from baseline (week 0) to end of treatment (week 52) is presented. In the reported data, 'Yes' infers percentage of participants who have achieved 15% weight loss whereas 'No' infers percentage of participants who have not achieved 15% weight loss. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

Time frame:
From baseline (week 0) to end of treatment (week 52)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving 15% Weight Loss (Yes/No)
Percentage of participantsSemaglutide 2.4 mgPlacebo
No56.197.9
Yes43.92.1
SecondaryPercentage of Participants Achieving 20% Weight Loss (Yes/No)

Percentage of participants who achieved 20% weight loss (yes/no) from baseline (week 0) to end of treatment (week 52) is presented. In the reported data, 'Yes' infers percentage of participants who have achieved 20% weight loss whereas 'No' infers percentage of participants who have not achieved 20% weight loss The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

Time frame:
From baseline (week 0) to end of treatment (week 52)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving 20% Weight Loss (Yes/No)
Percentage of participantsSemaglutide 2.4 mgPlacebo
No76.499.6
Yes23.60.4
SecondaryPercentage of Participants Improving 5 Points or More in KCCQ Clinical Summary Score (Yes/No)

Percentage of participants improving 5 points or more in KCCQ-CSS from baseline to end of treatment is presented. The KCCQ is standardized 23-item, self-administered instrument that quantifies heart failure symptoms(frequency, severity, and recent change), physical limitation, quality of life, and social limitation. KCCQ-CSS includes the symptom and physical limitation domains of the KCCQ. Scores are transformed to range of 0-100, in which higher scores reflect better health status. In the reported data, 'Yes' infers percentage of participants who have improved 5 points or more in score whereas 'No' infers percentage of participants who have not improved 5 points or more in score. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

Time frame:
From baseline (week 0) to end of treatment (week 52)
Reported as:
Number · Percentage of participants
Percentage of Participants Improving 5 Points or More in KCCQ Clinical Summary Score (Yes/No)
Percentage of participantsSemaglutide 2.4 mgPlacebo
No24.736.3
Yes75.363.7
SecondaryPercentage of Participants Improving 10 Points or More in KCCQ Clinical Summary Score (Yes/No)

Percentage of participants improving 10 points or more in KCCQ-CSS from baseline to end of treatment is presented. The KCCQ is standardized 23-item, self-administered instrument that quantifies heart failure symptoms(frequency, severity, and recent change), physical limitation, quality of life, and social limitation. KCCQ-CSS includes the symptom and physical limitation domains of the KCCQ. Scores are transformed to range of 0-100, in which higher scores reflect better health status. In reported data, 'Yes' infers percentage of participants who have improved 5 points or more in score whereas 'No' infers percentage of participants who have not improved 10 points or more in score. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

Time frame:
From baseline (week 0) to end of treatment (week 52)
Reported as:
Number · Percentage of participants
Percentage of Participants Improving 10 Points or More in KCCQ Clinical Summary Score (Yes/No)
Percentage of participantsSemaglutide 2.4 mgPlacebo
No36.651.5
Yes63.448.5
SecondaryChange in KCCQ Overall Summary Score (KCCQ-OSS)

The KCCQ is a standardized 23-item, self-administered instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, quality of life, and social limitation. The overall summary score and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. KCCQ-CSS includes the symptom and physical limitation domains of the KCCQ while KCCQ-OSS includes the symptom, physical limitation, quality of life, and social limitation domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

Time frame:
From baseline (week 0) to end of treatment (week 52)
Reported as:
Mean · Score on a scale
Change in KCCQ Overall Summary Score (KCCQ-OSS)
Score on a scaleSemaglutide 2.4 mgPlacebo
Change in KCCQ Overall Summary Score (KCCQ-OSS)16.8 ± 18.310.9 ± 17.5
SecondaryPercentage of Participants Achieving Threshold for Clinically Meaningful Within-participants Change in KCCQ-CSS (PGI-S)

The patient global impression of status (PGI-S) for KCCQ was used to rate participants' symptoms of heart failure using 4-category ordinal scale (no symptoms, mild, moderate, severe). KCCQ is standardized 23-item, self-administered instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, quality of life, and social limitation. OSS and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. KCCQ-CSS includes symptom and physical limitation domains of the KCCQ. Scores are transformed to range of 0-100, in which higher scores reflect better health status. Outcome measure was evaluated based on data from in-trial period. In-trial period was defined as uninterrupted time interval from date of randomization to date of last contact with trial site. The threshold was defined as mean change in KCCQ-CSS in those participants with one-category improvement in PGI-S from baseline to week 52.

Time frame:
From baseline (week 0) to end of treatment (week 52)
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Threshold for Clinically Meaningful Within-participants Change in KCCQ-CSS (PGI-S)
Percentage of ParticipantsSemaglutide 2.4 mgPlacebo
Percentage of Participants Achieving Threshold for Clinically Meaningful Within-participants Change in KCCQ-CSS (PGI-S)43.232.5
SecondaryPercentage of Participants Achieving Threshold for Clinically Meaningful Within-participants Change in 6MWD (PGI-S)

Observed mean change from baseline in 6 minutes walking distance (6MWD) test using PGI-S is evaluated for this outcome measure. The 6MWD is a common test of functional exercise capacity that assesses the distance a participant can walk in 6 minutes. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site. The threshold was defined as the mean change in 6MWD in those participants with an one-category improvement in PGI-S from baseline to week 52.

Time frame:
From baseline (week 0) to end of treatment (week 52)
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Threshold for Clinically Meaningful Within-participants Change in 6MWD (PGI-S)
Percentage of ParticipantsSemaglutide 2.4 mgPlacebo
Percentage of Participants Achieving Threshold for Clinically Meaningful Within-participants Change in 6MWD (PGI-S)42.528.0
SecondaryChange in Systolic Blood Pressure (SBP)

Observed mean change in systolic blood pressure from baseline (week -2) to end of treatment (week 52) is presented. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

Time frame:
From baseline (week -2) to end of treatment (week 52)
Reported as:
Mean · millimetre of mercury (mmHg)
Change in Systolic Blood Pressure (SBP)
millimetre of mercury (mmHg)Semaglutide 2.4 mgPlacebo
Change in Systolic Blood Pressure (SBP)-6.4 ± 19.0-1.1 ± 17.5
SecondaryChange in Waist Circumference

Change waist circumference from baseline (week 0) to end of the treatment (visit 52) presented. Waist circumference is defined as the abdominal circumference located midway between the lower rib margin and the iliac crest. Measurement must be obtained in standing position with a non-stretchable measuring tape and to the nearest cm or inch. The tape should touch the skin but not compress soft tissue and twists in the tape should be avoided. The participant should be asked to breathe normally. The same measuring tape should be used throughout the trial. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

Time frame:
From baseline (week 0) to end of treatment (visit 52)
Reported as:
Mean · Centimeter
Change in Waist Circumference
CentimeterSemaglutide 2.4 mgPlacebo
Change in Waist Circumference-12.0 ± 8.5-2.8 ± 7.4

Adverse events

Collected over From baseline (week 0) to end of trial (week 57). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Semaglutide 2.4 mg3/263 (1.1%)35/263 (13.3%)93/263 (35.4%)
Placebo4/266 (1.5%)71/266 (26.7%)57/266 (21.4%)
Most frequent serious events
Showing 10 of 110
Most frequent serious events
EventSemaglutide 2.4 mgPlacebo
Cardiac failureCardiac disorders0/26312/266
Atrial fibrillationCardiac disorders3/2639/266
Acute kidney injuryRenal and urinary disorders5/2631/266
DiarrhoeaGastrointestinal disorders3/2630/266
Atrial flutterCardiac disorders0/2633/266
COVID-19Infections and infestations0/2633/266
Cardiac failure congestiveCardiac disorders0/2633/266
CellulitisInfections and infestations1/2633/266
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/2633/266
AppendicitisInfections and infestations2/2630/266
Most frequent other events
Most frequent other events
EventSemaglutide 2.4 mgPlacebo
NauseaGastrointestinal disorders45/2637/266
COVID-19Infections and infestations36/26341/266
DiarrhoeaGastrointestinal disorders24/26310/266
ConstipationGastrointestinal disorders17/2637/266
VomitingGastrointestinal disorders17/2633/266

Baseline characteristics

Full analysis set (FAS) population included all the randomized participants for this trial.

Age, Continuous
Age, Continuous(years)Semaglutide 2.4 mgPlaceboTotal
Mean69 ± 968 ± 1068 ± 10
Sex: Female, Male
Sex: Female, Male(Participants)Semaglutide 2.4 mgPlaceboTotal
Female149148297
Male114118232
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Semaglutide 2.4 mgPlaceboTotal
Hispanic or Latino152136
Not Hispanic or Latino248245493
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Semaglutide 2.4 mgPlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American81321
White255252507
More than one race000
Unknown or Not Reported011
08

Study locations

146 sites
  • Eastern Shore Rsrch Inst, LLC
    Fairhope, Alabama 36532, United States
  • National Heart Institute Cal
    Beverly Hills, California 90211, United States
  • Keck Medical Center of USC - Outpatient Clinic
    Los Angeles, California 90033, United States
  • Lundquist Inst-Biomed Innovtn
    Torrance, California 90502, United States
  • Jacksonville Ctr For Clin Res
    Jacksonville, Florida 32216, United States
  • First Coast Cardiovascular Institute
    Jacksonville, Florida 32257, United States
  • Baptist Heart Specialists_Jacksonville
    Jacksonville, Florida 32258, United States
  • CV Res Ctr of S Florida
    Miami, Florida 33173, United States
  • Endeavor Health Clinical Operations-NCH
    Arlington Heights, Illinois 60005, United States
  • University of Chicago Medicine
    Chicago, Illinois 60637, United States
  • Endeavor Health Glenbook Hosp
    Evanston, Illinois 60201, United States
  • Northwestern University_Chicago_0
    Evanston, Illinois 60208, United States
  • Chicago Medical Research LLC
    Hazel Crest, Illinois 60429, United States
  • Ascension St. Vincent Medical Group
    Indianapolis, Indiana 46260, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center_Kansas City
    Kansas City, Kansas 66160, United States
  • Cotton-O'Neil Heart Center
    Topeka, Kansas 66606, United States
  • The Research Group of Lexington LLC
    Lexington, Kentucky 40503, United States
  • Baptist Health Louisville
    Louisville, Kentucky 40207, United States
  • Baptist Health Madisonville, Inc
    Madisonville, Kentucky 42431, United States
  • Grace Research, LLC
    Bossier City, Louisiana 71111, United States
  • Heart Clinic of Hammond
    Hammond, Louisiana 70403, United States
  • Grace Research, LLC_Shreveport
    Shreveport, Louisiana 71105, United States
  • Louisiana Heart Center_Slidell
    Slidell, Louisiana 70458, United States
  • Louisiana Heart Center
    Slidell, Louisiana 70458, United States
  • Ascension Saint Agnes Heart Ca
    Baltimore, Maryland 21229, United States
  • John Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202-2689, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55902, United States
  • Univ of Mississippi Med Ctr
    Jackson, Mississippi 39216, United States
  • Saint Luke's Hospital of Kansas City
    Kansas City, Missouri 64111, United States
  • St Louis Heart & Vascular, P.C.
    St Louis, Missouri 63136, United States
  • Bryan Heart
    Lincoln, Nebraska 68506, United States
  • CHI Health Clinic Cardiology (CUMC - Bergan Mercy)
    Omaha, Nebraska 68124, United States
  • St Francis Hospital Lindner Research Center
    Greenvale, New York 11548, United States
  • NY Presbyt Hosp-W Cornell Med
    New York, New York 10021, United States
  • Rochester General Hospital
    Rochester, New York 14621, United States
  • Wake Forest School of Medicine
    Winston-Salem, North Carolina 27157, United States
  • Lindner Center,Christ Hospital
    Cincinnati, Ohio 45219, United States
  • Abington Memorial Hospital
    Abington, Pennsylvania 19001, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Hospital of University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Medical Univ of South Carolina_Charleston_0
    Charleston, South Carolina 29425, United States
  • Sanford Health_Sioux Falls
    Sioux Falls, South Dakota 57117, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • University of Utah School of Medicine
    Salt Lake City, Utah 84132, United States
  • Cardiology Consultants of Danville Inc.
    Danville, Virginia 24541, United States
  • Virginia Heart
    Falls Church, Virginia 22042, United States
  • Sentara Health Research Center
    Norfolk, Virginia 23507, United States
  • Virginia Commonwealth University Health System
    Richmond, Virginia 23298-5058, United States
  • CEMEDIC
    CABA, Buenos Aires C1440CFD, Argentina
  • Master Centre for Argentina
    San Carlos de Bolivar, Buenos Aires 1334, Argentina
  • Centro de Investigación y Prevención Cardiovascular
    CABA, C1061AAS., Argentina
  • Centro de Investigación y Prevención Cardiovascular
    CABA, C1119ACN, Argentina
  • CEMEDIC
    CABA, C1440CFD, Argentina
  • Cardiología Palermo Duplicate
    Ciudad Autónoma de Buenos Aire, 1425, Argentina
  • Cardiología Palermo
    Ciudad Autónoma de Buenos Aire, 1425, Argentina
  • Instituto de Cardiología de Corrientes
    Corrientes, W3400AMZ, Argentina
  • Consultorio Integral de Atención al Diabético
    Morón, B1708IFF, Argentina
  • Sanatorio Britanico S.A.
    Rosario, Santa Fe, S2000CVB, Argentina
  • The Canberra Hospital_Garran
    Garran, Australian Capital Territory 2605, Australia
  • Concord Repatriation General Hospital - Cardiology Department
    Concord, New South Wales 2139, Australia
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
  • Royal Brisbane Hospital
    Herston, Queensland 4029, Australia
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
  • Geelong Cardiology Research Unit
    Geelong, Victoria 3220, Australia
  • University of Calgary_Calgary
    Calgary, Alberta T2N 4Z6, Canada
  • Univ of Alberta Hosp Edmonton
    Edmonton, Alberta T6G 2B7, Canada
  • North Shore Heart Centre
    North Vancouver, British Columbia V7M 2H4, Canada
  • SMH Cardiology Clinical Trials Inc.
    Surrey, British Columbia V3V 0C6, Canada
  • St. Boniface Hospital
    Winnipeg, Manitoba R2H 2HA6, Canada
  • Cambridge Cardiac Care Centre
    Cambridge, Ontario N1R 6V6, Canada
  • Partnrs Adv Cardio Eval (PACE)
    Newmarket, Ontario L3Y 2P6, Canada
  • North York Diagn & Cardiac Ctr
    North York, Ontario M6B 3H7, Canada
  • Oakville Cardiovascular Research LP
    Oakville, Ontario L6K 3W7, Canada
  • Dr James Cha
    Oshawa, Ontario L1J 2K1, Canada
  • Heart Health Institute Research, Inc.
    Scarborough Village, Ontario M1B 4Z8, Canada
  • Dr. Louis Yao
    Weston, Ontario M9N 1W4, Canada
  • Clinique Sante Cardio MC
    Montreal, Quebec H1T 3Y7, Canada
  • Unv de Cardiologie et dePneum
    Québec, G1V 4G5, Canada
  • Nemocnice Jihlava Kardiologie
    Jihlava, 586 33, Czechia
  • Nemocnice Jihlava
    Jihlava, 586 33, Czechia
  • Vseobecna fakultni nemocnice a 1 LF UK v Praze
    Prague, 128 00, Czechia
  • Všeobecná fakultní nemocnice v Praze
    Prague, 128 00, Czechia
  • IKEM
    Prague, 140 21, Czechia
  • MEDICON a.s.
    Prague, 170 00, Czechia
  • Poliklinika Holešovice VISIONARY - Medicon Pharm s.r.o.
    Prague, 170 00, Czechia
  • Nemocnice Slany Kardiologie
    Slaný, 274 01, Czechia
  • Nemocnice Tábor a.s.
    Tábor, 390 03, Czechia
  • Herlev og Gentofte Hospital
    Hellerup, Capital Region 2900, Denmark
  • Aarhus Universitetshospital, Hjertesygdomme
    Aarhus N, 8200, Denmark
  • Kardiologisk Odense & Svendborg
    Svendborg, 5700, Denmark
  • Charité - Campus Virchow-Klinikum - Kardiologie, Angiologie und Intensivmedizin (CRU)
    Berlin, 13353, Germany
  • Cardiologicum Dresden und Pirna - MVZ "Am Felsenkeller" (Dresden)
    Dresden, 01277, Germany
  • Zentrum fuer klinische Studien Suedbrandenburg GmbH
    Elsterwerda, 04910, Germany
  • MVZ CCB Frankfurt und Main-Taunus GbR
    Frankfurt, 60389, Germany
  • Medical Center - University Of Freiburg
    Freiburg im Breisgau, 79106, Germany
  • Universitätsklinikum Freiburg - Medical Center
    Freiburg im Breisgau, 79106, Germany
  • Appel
    Kassel, 34121, Germany
  • B. Braun Ambulantes Herzzentrum Kassel MVZ GmbH
    Kassel, 34121, Germany

Showing the first 100 of 146 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Borlaug BA, Kitzman DW, Davies MJ, Rasmussen S, Barros E, Butler J, Einfeldt MN, Hovingh GK, Moller DV, Petrie MC, Shah SJ, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Nunez J, Perna E, Schou M, Senni M, van der Meer P, Von Lewinski D, Wolf D, Kosiborod MN. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat Med. 2023 Sep;29(9):2358-2365. doi: 10.1038/s41591-023-02526-x. Epub 2023 Aug 27. PubMed 37635157 ↗
  • Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Moller DV, Shah SJ, Treppendahl MB, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, Nunez J, Perna E, Schou M, Senni M, Sharma K, Van der Meer P, von Lewinski D, Wolf D, Petrie MC; STEP-HFpEF Trial Committees and Investigators. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023 Sep 21;389(12):1069-1084. doi: 10.1056/NEJMoa2306963. Epub 2023 Aug 25. PubMed 37622681 ↗
  • Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, Emerson SS, Kahn SE, Kitzman DW, Lingvay I, Mahaffey KW, Petrie MC, Plutzky J, Rasmussen S, Ronnback C, Shah SJ, Verma S, Weeke PE, Lincoff AM; SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM Trial Committees and Investigators. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024 Sep 7;404(10456):949-961. doi: 10.1016/S0140-6736(24)01643-X. Epub 2024 Aug 30. PubMed 39222642 ↗
  • Shah SJ, Sharma K, Borlaug BA, Butler J, Davies M, Kitzman DW, Petrie MC, Verma S, Patel S, Chinnakondepalli KM, Einfeldt MN, Jensen TJ, Rasmussen S, Asleh R, Ben-Gal T, Kosiborod MN. Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials. Eur Heart J. 2024 Sep 14;45(35):3254-3269. doi: 10.1093/eurheartj/ehae322. PubMed 38739118 ↗
  • Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrom SZ, Davies MJ, Hovingh GK, Kitzman DW, Moller DV, Verma S, Einfeldt MN, Lindegaard ML, Rasmussen S, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, Nunez J, Perna E, Schou M, Senni M, Sharma K, van der Meer P, Von Lewinski D, Wolf D, Kosiborod MN; STEP-HFpEF Trial Committees and Investigators. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024 Apr 27;403(10437):1635-1648. doi: 10.1016/S0140-6736(24)00469-0. Epub 2024 Apr 7. PubMed 38599221 ↗
  • Butler J, Abildstrom SZ, Borlaug BA, Davies MJ, Kitzman DW, Petrie MC, Shah SJ, Verma S, Abhayaratna WP, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Nunez J, Perna E, Schou M, Senni M, van der Meer P, von Lewinski D, Wolf D, Altschul RL, Rasmussen S, Kosiborod MN. Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction. J Am Coll Cardiol. 2023 Nov 28;82(22):2087-2096. doi: 10.1016/j.jacc.2023.09.811. Epub 2023 Oct 8. PubMed 37993201 ↗
  • Kosiborod MN, Verma S, Borlaug BA, Butler J, Davies MJ, Jon Jensen T, Rasmussen S, Erlang Marstrand P, Petrie MC, Shah SJ, Ito H, Schou M, Melenovsky V, Abhayaratna W, Kitzman DW; STEP-HFpEF Trial Committees and Investigators. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial. Circulation. 2024 Jan 16;149(3):204-216. doi: 10.1161/CIRCULATIONAHA.123.067505. Epub 2023 Nov 12. PubMed 37952180 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Apr 2023, 25 months.

Results were first posted in Jun 2024, 1 year 1 month after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 25 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2021
First posted
Mar 9, 2021
StartActual
Mar 16, 2021
Primary completionActual
Apr 18, 2023
CompletionActual
Apr 18, 2023
Results first posted
Jun 11, 2024
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04788511
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 9, 2021
Start date
Mar 16, 2021
Primary completion
Apr 18, 2023
Completion
Apr 18, 2023
Results posted
Jun 11, 2024
Last update
Dec 5, 2025

Study contacts

Clinical Transparency (dept. 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion